Healthcare Industry News: Merck
News Release - December 1, 2017
EMD Serono Appoints Zhen Su, M.D., MBA to Chief Medical Officer, North AmericaROCKLAND, Mass., Dec. 1, 2017 -- (Healthcare Sales & Marketing Network) -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced the appointment of Zhen Su, M.D., MBA as Chief Medical Officer for North America. In this role, Dr. Su will collaborate with the local and global medical, development and regulatory teams to drive the progress of EMD Serono's portfolio and pipeline, as well as enhance scientific leadership in the US.
"Zhen has made significant contributions to our organization through his previous positions, including building our US oncology medical affairs team from the ground up and leading multiple global oncology launches this past year," said Gary Zieziula, President and Managing Director, EMD Serono. "Zhen has the strategic vision and medical leadership to help develop and move our growing portfolio and pipeline of compounds forward for patients in need."
Dr. Su's expertise complements the global organization's R&D strategy, which focuses on delivering a transformative pipeline in the core therapeutic areas of oncology, immuno-oncology and immunology with several high-priority programs in late development, as well as a number of promising early-stage assets.
A physician executive with more than 20 years of experience, Dr. Su held roles at a number of academic institutions – including Duke University and University of Florida, where he led early clinical development in Immuno-Oncology as a faculty member – before joining the biopharmaceutical industry. Within EMD Serono, he most recently held the position of Global Head of Medical Affairs, Oncology, prior to which, he held leadership roles in general management, clinical development and medical affairs at Sanofi and GlaxoSmithKline.
Dr. Zhen Su will be based in Rockland, Mass.
Dr. Su earned his MD degree from the Technical University of Dresden, Germany and completed his MBA training at the University of Toronto, Canada.
About EMD Serono, Inc.
EMD Serono is the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada - a leading science and technology company - focused exclusively on specialty care. For more than 40 years, the business has integrated cutting-edge science, innovative products and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in oncology, immuno-oncology and immunology as R&D focus areas. Today, the business has 1,300 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts. www.emdserono.com
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck KGaA, Darmstadt, Germany, generated sales of € 15.0 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the "Merck" name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Source: EMD Serono
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.